|
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) |
|
Amneal Pharmaceuticals Inc
AMRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Amneal Pharmaceuticals Inc growth rates, revenue grew
by 31.27 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1161
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Amneal Pharmaceuticals Inc faced net loss in contrast to the net income a year ago in IV. Quarter 2024
• More on AMRX's Growth
|
|
Amneal Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 96.68 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.79.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on AMRX's Valuation
|
|
|
|
|
Amneal Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 96.68 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.79.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on AMRX's Valuation
|
|
AMRX's Profitability Comparisons
|
Amneal Pharmaceuticals Inc faced margin deterioration, primarily through cost control. Operating Margin fell in IV. Quarter 2024 to 11.76 % from 12.66 % in III. Quarter.
Profitability by Segment |
Generics |
41.65 % |
Specialty |
54.74 % |
AvKARE |
17.72 % |
Total |
1.68 % |
|
|
Amneal Pharmaceuticals Inc faced margin deterioration, primarily through cost control. Operating Margin fell in IV. Quarter 2024 to 11.76 % from 12.66 % in III. Quarter.
• More on AMRX's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com